Hematopoyetic and lymphoid tumors
PRINCIPAL INVESTIGATORS
- Victòria Clapés Puig
- Sonia González Rodríguez
- Eva González Barca
- Octavio Servitje Bedate
- Montserrat Arnan Sangerman
- Eva Domingo Domènech
CLINICAL RESEARCHERS
- Ana Carla De Oliveira Ramos
- Clara Maluquer Artigal
- Alberto Mussetti
Cancer
Oncobell
Scientific production
58
PAPERS
Average IF: 12,28
14
LED PAPERS
Average IF: 4,47
15 PUBLICATIONS IN FIRST DECILE
38 PUBLICATIONS IN FIRST QUARTILE
42 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Westin,JR;Oluwole,OO;Kersten,MJ;Miklos,DB;Perales,MA;Ghobadi,A;Rapoport,AP et al, Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma, N. Engl. J. Med., 2023;389(2):148-157, doi:10.1056/NEJMoa2301665
- Cortellini,A;Tabernero,J;Mukherjee,U;Salazar,R;Sureda,A;Maluquer,C;Ferrante,D et al, SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry, Lancet Oncol., 2023;24(4):335-346, doi:10.1016/S1470-2045(23)00056-6
- Zinzani,PL;Mayer,J;Flowers,CR;Bijou,F;De Oliveira,AC;Song,Y;Zhang,Q et al, ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma., J. Clin. Oncol., 2023;41(33):5107-5117, doi:10.1200/JCO.23.00775
- Maggioni,G;Bersanelli,M;Travaglino,E;Pierola,AA;Kasprzak,A;Montserrat,AS;Sauta,E et al, A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study, Lancet Haematol., 2023;10(2):117-128, doi:10.1016/S2352-3026(22)00323-4
- Dreger,P;Corradini,P;Gribben,JG;Glass,B;Jerkeman,M;Kersten,MJ;Morschhauser,F et al, CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach., Lancet Haematol., 2023;10(12):1006-1015, doi:10.1016/S2352-3026(23)00307-1
Research highlights
PROJECTS
2 Granted competitive projects
7 Ongoing competitive projects
33 Started clinical trials
125 Ongoing clinical trials
2 Ongoing non competitive projects
PUBLISHED WORKS
2 Clinical guidelines
NETWORKS
AGAUR SGR GRC
RIC-TEV-2020
Selected projects
- 2023-751-1. PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. REGENERON PHARMACEUTICAL, INC . Budget: 761.371,2€. 2023- . PI: Sureda Balari, Anna.
- 20ACL045. ENSAYO EN FASE 1 DESTINADO A EVALUAR LA SEGURIDAD, LOS PERFILES FARMACOCINÉTICOS Y LA EFICACIA DEL EDO-S101, UN NUEVO FÁRMACO ALQUILANTE DE FUSIÓN DE HDACI PARA EL TRATAMIENTO DE TUMORES HEMATOLÓGICOS MALIGNOS EN RECIDIVA O REFRACTARIOS.. Mundipharma Pharmaceuticals, S.L.;MUNDIPHARMA RESEARCH LTD. Budget: 392.839,2€. 2020- . PI: Sureda Balari, Anna.
- 2023-323-1. Estudio de prueba de concepto de fase Ib/II, abierto y de confirmación de dosis de siremadlin en combinación con venetoclax más azacitidina en participantes adultos con LMA no aptos para quimioterapia y con una respuesta subóptima al tratamiento de primera línea con venetoclax más azacitidina, y en participantes con LMA de nuevo diagnóstico, no aptos para quimioterapia y que presenten características clínicas de alto riesgo. Novartis Farmacéutica, S.A.. Budget: 321.492€. 2023- . PI: Arnan Sangerman, Montserrat.
- 2024-011-1. AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANTINELIGIBLE PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA. Pfizer, Inc . Budget: 297.463,65€. 2023- . PI: Sureda Balari, Anna.
- 20ACL103. SAFETY AND EFFICACY OF GEN3009 (DUOHEXABODY®-CD37) IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA – A FIRST-IN-HUMAN, OPEN-LABEL, PHASE I/IIA DOSE ESCALATION TRIAL WITH DOSE EXPANSION COHORTS. IQVIA RDS Spain SL. Budget: 288.775€. 2020- . PI: Sureda Balari, Anna.